Sunday, August 31, 2014 Last update: 12:33 AM
FreshNews.com - All Company Technology News Since 1996

The Zacks Analyst Blog Highlights: Herbalife, Nu Skin, Avon Products, Bayer and Amgen

Companies mentioned in this article: Zacks Investment Research, Inc.

CHICAGO, March 13, 2014 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Herbalife Ltd (NYSE:HLF-Free Report), Nu Skin Enterprises Inc (NYSE:NUS-Free Report), Avon Products Inc (NYSE:AVP-Free Report), Bayer (OTC:BAYRY-Free Report) and Amgen Inc. (Nasdaq:AMGN-Free Report).

http://photos.prnewswire.com/prnvar/20101027/ZIRLOGO

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Wednesday's Analyst Blog:

Herbalife Faces Another Ackman Attack

Herbalife Ltd (NYSE:HLF-Free Report) finds itself facing yet another accusation by activist investor Bill Ackman, hedge fund manager of Pershing Square, for operating illegally in China, as per media reports. Shares of this nutritionist company fell 1.16% yesterday after the news.

The billionaire investor told his clients that Herbalife is likely violating multi-level market restrictions in China. Ackman pointed to internal documents obtained from a former employee at Herbalife and argued that the company's Chinese operations were identical to its business in other countries such as the United States and Mexico. However, this can be risky for Herbalife as Chinese law prohibits any multilevel marketing structure.

Herbalife responded to Ackman and stated that its business model is in compliance with Chinese direct-selling and anti-pyramid regulations. Earlier in Jan 2014, First Financial Daily, a Chinese newspaper, also suspected that Herbalife adopted illegal marketing practices in China. Later in Jan 2014, the Canadian Competition Bureau announced a formal investigation into the pyramid scheme business model complaints against the company, as per a report by theNew York Post.

Over the past 14 months, Ackman has been accusing Herbalife of running a pyramid scheme business model. i.e. it employs deceptive marketing practices for improving business. The company was accused of making money by recruiting new sales people and not from its sales.

Ackman made that claim in Dec 2012 when he unveiled a $1 billion short position in the company's shares. Ackman even sent a letter to its investors on Dec 24, 2013 about the improper recruiting methods adopted by Herbalife.

Reportedly, Ackman tried to lobby Congress members to push for an investigation against Herbalife by state and federal regulators, especially the Federal Trade Commission. Such an attempt shows that Ackman is determined to prove the charges. Herbalife, on the other hand, has been denying all the charges and is confident about its operations.

Herbalife is not the only company, which employs sales representatives to sell its products. Other multi-level marketing companies like Nu Skin Enterprises Inc (NYSE:NUS-Free Report) and Avon Products Inc (NYSE:AVP-Free Report) also follow the same distribution model.

We appreciate the fact that despite allegations numerous attacks on its multi-level marketing model, the company's earnings continue to increase. This signals that the stock has potential and will continue to move higher, going ahead.

Herbalife holds a Zacks Rank #2 (Buy).

Bayer/Amgen's Nexavar Fails Late-Stage Study

The HealthCare segment at Bayer (OTC:BAYRY-Free Report) and partner, Amgen Inc. (Nasdaq:AMGN-Free Report), announced disappointing results from a phase III STORM (Sorafenib as Adjuvant Treatment in the Prevention of Recurrence of Hepatocellular Carcinoma) study on Nexavar.

The study was evaluating the clinical benefit of Nexavar compared to placebo as an adjuvant treatment for patients suffering from hepatocellular carcinoma who had no detectable disease following surgical resection or local ablation.

Bayer stated that Nexavar failed to meet the primary objective of the study of improving recurrence-free survival. However, the companies mentioned that the safety findings were consistent with Nexavar's known profile.

We are disappointed with the study outcome. Bayer's shares went down slightly following the news. Bayer is, however, not losing hope and stated in its press release that it will continue to explore the full potential of Nexavar in all stages of liver cancer. As per company sources over 780,000 liver cancer patients are diagnosed each year worldwide.

Nexavar is already a key oncology product at Bayer and is approved in over 100 countries around the globe. In the U.S., the drug is approved for the treatment of patients suffering from locally recurrent or metastatic, progressive, differentiated thyroid cancer (DTC) that is refractory to radioactive iodine treatment.

In the EU, the drug is approved for two other indications - for the treatment of patients suffering from hepatocellular carcinoma and suffering from advanced renal cell carcinoma who have had unsuccessful interferon-alpha or interleukin-2 based therapy.

Bayer reported Nexavar sales of EUR771 million in 2013, up 3.3% year over year on an adjusted basis. Bayer and Amgen are evaluating Nexavar in several other indications as well. We expect Nexavar sales to be boosted with further label expansions.

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.

Get the full Report on HLF - FREE
Get the full Report on NUS - FREE
Get the full Report on AVP - FREE
Get the full Report on BAYRY - FREE
Get the full Report on AMGN - FREE

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Logo - http://photos.prnewswire.com/prnh/20101027/ZIRLOGO

SOURCE Zacks Investment Research, Inc.